| dc.creator | Conran | |
| dc.creator | Nicola | |
| dc.date | 2015-MAY | |
| dc.date | 2016-06-07T13:17:21Z | |
| dc.date | 2016-06-07T13:17:21Z | |
| dc.date.accessioned | 2018-03-29T01:37:54Z | |
| dc.date.available | 2018-03-29T01:37:54Z | |
| dc.identifier | | |
| dc.identifier | Prospects For Early Investigational Therapies For Sickle Cell Disease. Informa Healthcare, v. 24, p. 595-602 MAY-2015. | |
| dc.identifier | 1354-3784 | |
| dc.identifier | WOS:000352648800001 | |
| dc.identifier | 10.1517/13543784.2015.1012292 | |
| dc.identifier | http://www.tandfonline.com/doi/full/10.1517/13543784.2015.1012292 | |
| dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/242299 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1305997 | |
| dc.description | Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal hemoglobin that polymerizes at low oxygen concentrations, causing the erythrocyte to adopt a sickle-shaped morphology. SCD pathophysiology is extremely complex and can lead to numerous clinical complications, including painful vaso-occlusive crises (VOC), end-organ damage, and a shortened lifespan. An impressive number of investigational drugs are currently in early stages of clinical development with prospects for use either as chronic therapies to reduce VOC frequency and end-organ damage in SCD or for use at the time of VOC onset. Many of these agents have been developed using a pathophysiological-based approach to SCD, targeting one or more of the mechanisms that contribute to the disease process. It is plausible that a multi-drug approach to treating the disease will evolve in the coming years, whereby hydroxyurea (HU) (the only drug currently FDA-approved for SCD) is used in combination with drugs that amplify nitric oxide signaling and/or counteract hemolytic effects, platelet activation and inflammation. | |
| dc.description | 24 | |
| dc.description | 5 | |
| dc.description | | |
| dc.description | 595 | |
| dc.description | 602 | |
| dc.description | | |
| dc.description | | |
| dc.description | | |
| dc.language | en | |
| dc.publisher | INFORMA HEALTHCARE | |
| dc.publisher | | |
| dc.publisher | LONDON | |
| dc.relation | EXPERT OPINION ON INVESTIGATIONAL DRUGS | |
| dc.rights | embargo | |
| dc.source | WOS | |
| dc.subject | Acute Chest Syndrome | |
| dc.subject | Controlled-trial | |
| dc.subject | Oxygen-affinity | |
| dc.subject | Pain Episodes | |
| dc.subject | Double-blind | |
| dc.subject | Hemoglobin | |
| dc.subject | Hydroxyurea | |
| dc.subject | Placebo | |
| dc.subject | Crisis | |
| dc.subject | Mice | |
| dc.title | Prospects For Early Investigational Therapies For Sickle Cell Disease | |
| dc.type | Artículos de revistas | |
| dc.type | Artículos de revistas | |
